New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

FYARRO (sirolimus protein-bound particles for injectable suspension)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

INDICATIONS AND USAGE
Fyarro (sirolimus protein-bound particles) (albumin-bound) is a prescription medicine used for advanced malignant perivascular epithelioid cell tumor (PEComa) in adults.
DOSAGE FORMS & STRENGTHS: For injectable suspension: lyophilized powder containing 100 mg of sirolimus formulated as albumin-bound particles in single-dose vial for reconstitution.
Manufactured By: Aadi Bioscience
Prescribing Information URL: Click Here

FYARRO (sirolimus protein-bound particles for injectable suspension), a FDA approved prescription medicine can be accessed in India and other part of countries. South Delhi Pharma can facilitate the supply on request under Named Patient Program by fulfilling the legal requirement (if applicable) on behalf patient. Share your mobile number and email ID to get “sirolimus protein-bound particles for injectable suspension injections” cost price in India.

Category
FYARRO (sirolimus protein-bound particles for injectable suspension) cost Price In India
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Medical Uses of sirolimus protein-bound particles for injectable suspension injection

Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of lymphangioleiomyomatosis (LAM). Sirolimus (Fyarro), as protein-bound particles, is indicated for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mechanistic target of rapamycin kinase (mTOR) inhibitor that inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2). It was approved by the U.S. Food and Drug Administration (FDA) in September 1999.

Get Access To FYARRO (sirolimus protein-bound particles for injectable suspension) injection In India

Brand Name “FYARRO (sirolimus protein-bound particles for injectable suspension) injection” or Generic Name “sirolimus protein-bound particles for injectable suspension injection” can be imported for personal use under “Named Patient Program” treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.

Related Products